Antihypertensive medication and dementia risk in patients with hypertension: A nationwide population-based study
Chih-Ying Lin,Pei-Hsien Chen,Chiu-Lin Tsai,Yow-Wen Hsieh,Kai-Chieh Hu,Fuu-Jen Tsai,Der-Yang Cho,Hsien-Yin Liao
DOI: https://doi.org/10.1016/j.jocn.2024.05.006
IF: 2.116
2024-05-18
Journal of Clinical Neuroscience
Abstract:The claim between hypertension and dementia needs more evidence due to limited data. We aim to examine the risk of dementia in patients with hypertension, and determine whether the use of antihypertensive medications (AHMs) could decrease the incidence of dementia diagnosed following the onset of hypertension. We employed the Taiwan National Health Insurance Research Database from 2000 to 2016 and performed a retrospective cohort study. We also carried out a case-control study to see if AHMs could reduce the incidence of newly diagnosed dementia in hypertensive patients. In the retrospective cohort study, we selected 587,762 participants with age and gender matched in experimental and control groups. The hypertension group had significantly higher adjusted hazard ratios (aHRs) of getting newly diagnosed dementia, including all-cause dementia, Alzheimer's disease, and vascular dementia (aHR, 2.86; 95 % confidence interval (CI), 2.74–2.99) than the control group. Three kinds of specific AHMs, namely, angiotensin II receptor blockers (aHR, 0.55; 95 % CI, 0.53–0.57), calcium channel blockers (aHR, 0.76; 95 % CI, 0.73–0.80), and diuretics (aHR,0.93; 95 % CI, 0.89–0.97) could significantly decrease the incidence of getting newly diagnosed dementia. Also, the application of traditional Chinese medicine (TCM) significantly associates with the lower aHRs of newly diagnosed dementia in hypertensive patients compared to patients without TCM (aHR, 0.90; 95 % CI, 0.81–1.00). Hypertension may be a significant risk factor for dementia. Both AHMs and TCM significantly associate with the lower incidence of newly diagnosed dementia in hypertensive patients.
neurosciences,clinical neurology